SLC5A2 and cancer: While their primary antidiabetic action is attributed to suppressing glucose uptake, SGLT2 inhibitors exhibit multiple mechanisms to combat cancer, such as down-regulating oxidative phosphorylation, increasing cell cycle arrest and apoptosis, suppressing β-catenin and PI3K-Akt pathways, and causing mitochondrial membrane instability.